Athletes are always looking for the next great “it” supplement that will enhance their performance, increase their gains, and push them past the competition. Each year brings with it the promise of new ingredients, with each claiming to be the next big thing.
Unfortunately, most of these supplements end up being more bark than bite. But every once in awhile, a new ingredient comes along that’s worthy of the hype and brings with it the promise of significantly enhanced performance.
One of the newest supplements to fall into this category is a little ingredient called VasoDrive-AP. It’s brand new on the scene, and not found in very many products, but when you start to understand what this powerful little compound can do, you’ll be clamoring for it in your pre workout.
Let’s find out what it is!
What is VasoDrive AP?
VasoDrive-AP is a patented, proprietary ingredient derived from casein (yep, the same stuff used in protein powders!). It’s also known as AmealPeptide®, but for our purposes here, we’ll stick with the much cooler sounding VasoDrive-AP version.
VasoDrive is a combination of two casein-derived tripeptides in Valyl-Prolyl-Proline (VPP) and Isoleucyl-Prolyl-Proline(IPP). As you may or may not know, peptides are compounds consisting of two or more amino acids joined by peptide bonds. In the case of VasoDrive-AP, we have two tripeptides, which means each tripeptide is comprised of three individual amino acids. The three amino acids present are valine (one of the BCAAs), proline, and isoleucine (another BCAA).
You’re probably already wondering what’s so special about a collection of amino acids you could easily get from casein. Well, the unique fermentation and extraction process used by the developers of VasoDrive-AP (MayPro®) provide levels of VPP and IPP not practically achievable through regular dairy consumption.
Now, let’s take a deeper look at what this tripeptide does for you!
What does VasoDrive-AP do?
To answer it simply, VasoDrive-AP is going to be the next big pump ingredient to take the industry by storm. It’ll rank right alongside the likes of Citrulline, Agmatine, and Nitrates for pure blood-flowing, pump-swelling power!
More specifically, VasoDrive-AP inhibits a particular enzyme that causes blood vessels to constrict -- angiotensin converting enzyme (ACE).[1,2] Clinical research on VasoDrive-AP has shown that it normalizes blood pressure, maintains both systolic and diastolic blood pressure, and promotes arterial elasticity. Additionally, inhibiting ACE and/or blocking the angiotensin II receptor also improves insulin sensitivity, which is essential for optimal blood flow to skeletal muscles and ultimately a strong pump.[4,5] Plus, blocking the angiotensin II receptor also protects muscle cells against free radical related dysfunction and aging.[6,7,8]
However, the main reason we’re interested in it (especially as a pre workout ingredient) is the potential ergogenic effects it offers via reducing ACE activity in the body.[9,10,11] The reason we’re focusing so much on VasoDrive-AP and its effects regarding ACE is that sports science has uncovered that ACE is the first gene clearly identified to substantially impact physical performance. More specifically, the I-allele is associated with the lowest cardiac growth response, which is linked to endurance performance, while the D allele is associated with an “exaggerated response to training”, making it more associated with strength gains.
Research is still evolving on the topic of ACE genotypes and the mechanisms underlying their role in performance, but there’s no denying the fact that ACE inhibition can play a significant role in boosting your performance and pumps, so much so that ACE inhibitors are being investigated as possible doping agents elite athletes could use to “one up” the competition.
VasoDrive-AP for Bigger Pumps!
Ok, if all that science talk thoroughly confused you and you’re just wanting the short and simple version of how VasoDrive-AP impacts your performance, here it is:
With VasoDrive-AP in your pre workout, you’ll experience significantly increased blood flow, more pronounced vasodilation, and lower blood pressure. All of this adds up to greater nutrient / oxygen delivery to working muscles, allowing them to work harder for longer periods of time, and best of all you’ll be the recipient of some of the biggest, densest muscle pumps you’ve ever experienced!
And, there’s no need to worry about any GI upset from VasoDrive-AP (it is derived from milk after all), as it contains less than 0.05% lactose.
Ingredients like VasoDrive-AP don’t come along very often, but when they do, you’ll want absolutely want it as part of your pre workout. With it, you’ll experience greater performance, less fatigue, and dramatically bigger pumps. That’s something any athlete will take hand over fist.
FitzGerald RJ, Meisel H. Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Br J Nutr. 2000;84 Suppl 1:S33-37.
Hirota T, Ohki K, Kawagishi R, et al. Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. Hypertension research : official journal of the Japanese Society of Hypertension. 2007;30(6):489-496.
Fekete ÁA, Givens DI, Lovegrove JA. Casein-Derived Lactotripeptides Reduce Systolic and Diastolic Blood Pressure in a Meta-Analysis of Randomised Clinical Trials. Nutrients. 2015;7(1):659-681.
Baron AD, Brechtel-Hook G, Johnson A, Hardin D. Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension. 1993;21(2):129-135.
Mather KJ, Steinberg HO, Baron AD. Insulin resistance in the vasculature. J Clin Invest.123(3):1003-1004.
Kasper SO, Phillips EE, Castle SM, Daley BJ, Enderson BL, Karlstad MD. Blockade of the Renin-Angiotensin system improves insulin receptor signaling and insulin-stimulated skeletal muscle glucose transport in burn injury. Shock (Augusta, Ga.). 2011;35(1):80-85.
de Cavanagh EM, Piotrkowski B, Basso N, et al. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. Faseb J. 2003;17(9):1096- 1098.
Sartiani L, Spinelli V, Laurino A, et al. Pharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers? Clinical Cases in Mineral and Bone Metabolism. 2015;12(2):135-138. 21. Ondera G, Vedova CD, Pahorc M. Effects of ACE Inhibitors on Skeletal Muscle. Curr Pharm Des. 2006;12(16):2057-2064.
Folland J, Leach B, Little T, et al. Angiotensin-converting enzyme genotype affects the response of human skeletal muscle to functional overload. Experimental physiology. 2000;85(5):575-579.
Puthucheary Z, Skipworth JRA, Rawal J, Loosemore M, Van Someren K, Montgomery HE. The ACE gene and human performance. Sports medicine. 2011;41(6):433-448.
Puthucheary Z, Skipworth JR, Rawal J, Loosemore M, Van Someren K, Montgomery HE. The ACE gene and human performance: 12 years on. Sports Med. 2011;41(6):433-448.
Wang P, Fedoruk MN, Rupert JL. Keeping pace with ACE: are ACE inhibitors and angiotensin II type 1 receptor antagonists potential doping agents? Sports Med. 2008;38(12):1065-1079.
Kajimoto O, Aihara K, Hirata H, Takahashi R, Nakamura Y. [Hypotensive Effects of The Tablets Containing "Lactotripeptides (VPP, IPP)"]. Journal of Nutritional Food. 2001;4(3):51–61. Japanese.